November 11th, 2026Adverse pregnancy outcomes tied to postpartum contraceptive choicesPatients with 3 or more adverse pregnancy outcomes had lower odds of postpartum contraceptive use in a PRAMS analysis of 222,412 individuals.Read more
November 6th, 2026Maternal RSVpreF vaccine tied to fewer infant RSV hospitalizationsReal-world data show maternal RSVpreF vaccination was 82% effective against infant RSV LRTI hospitalization through 3 months.Read more
November 3rd, 2026Q&A: Peter Hsin, BS, on perioperative ketamine and early postpartum depressionPeter Hsin, BS, discusses a meta-analysis linking perioperative ketamine to lower early postpartum depressive symptoms after cesarean delivery.Read more
November 2nd, 2026FDA grants accelerated approval to DNA immunotherapy for adult recurrent respiratory papillomatosisThe FDA granted accelerated approval to Voceryq to reduce papilloma excision surgeries in adults with recurrent respiratory papillomatosis.Read more
October 30th, 2026Study does not support dose reduction to prevent severe NOWSNeither maternal MOUD dose nor umbilical cord opioid levels were associated with neonatal opioid withdrawal syndrome severity.Read more
October 28th, 2026ACOG advises against GLP-1 receptor agonists during pregnancyACOG advises against GLP-1 receptor agonists in pregnancy and recommends considering discontinuation 1 to 2 months before conception.Read more
November 13th, 2026Testosterone in women: Androgenic adverse events and lab monitoringBlood levels alone cannot confirm safe testosterone dosing. Asking about androgenic effects and allowing months for response are central to care.Read more
November 13th, 2026Testosterone for women: Global consensus and physiologic dosingA global consensus defines what the evidence supports for testosterone in women. Benefits for strength, mood, and cognition lack randomized data.Read more